Navigation Links
Quadruple therapy shows 100 percent SVR for HCV patients previously unresponsive to treatment
Date:4/2/2011

Berlin, Germany, Saturday 02 April 2011: Exciting new data presented today at the International Liver CongressTM 2011 show that quadruple therapy in chronic hepatitis C (HCV) patients suppressed the emergence of resistant variants and resulted in a 100% rate of sustained virological response - undetectable HCV RNA - 12 weeks after treatment (SVR12).1

In the quadruple therapy study, HCV patients were given four drugs in combination; pegylated Interferon-alpha (PegIFN-alpha); ribavirin (RBV); and two different direct-acting antivirals (DAAs) BMS-650032 (an HCV NS3 protease inhibitor) and BMS-790052 (an HCV NS5A replication complex inhibitor).

The current standard of care (SoC) for HCV therapy is PegIFN-alpha plus RBV a dual therapy. The addition of DAAs (currently in phase-III clinical trials) marks the next step in treatment evolution a triple therapy. However, the new data presented today suggests that quadruple therapy could be the next generation of treatment for chronic HCV patients.

Professor Heiner Wedemeyer, EASL'S Secretary General, said: "Quadruple therapy is possibly the future of HCV treatment; this study goes a way to confirming that. While it's expected that the first DAAs and triple therapy will be approved for use later this year, quadruple therapy appears to have a more profound effect on virological response, with less of a resistance problem."

The study may also provide new hope for a growing number of HCV patients who cannot be effectively treated for chronic hepatitis with current treatments.

The Phase-IIa trial looked at a cohort of 21 HCV genotype 1 null responders (patients who have failed to respond to previous treatment), of whom 19 had an unfavourable IL28B genotype, which predisposes HCV patients to treatment failure.

Only about 30% of null responders to PegIFN-alpha/RBV treatment achieve sustained virological response (SVR) when retreated with PegIFN-alpha/RBV plus telaprevir, demonstrating a high unmet medical need.1


'/>"/>

Contact: Travis Taylor
easlpressoffice@cohnwolfe.com
44-784-306-9451
European Association for the Study of the Liver
Source:Eurekalert

Related medicine news :

1. Insulin could be Alzheimers therapy
2. Early Brain Therapy May Help Movement in Dystonia Patients
3. New approach to leukemia chemotherapy -- is a cure in sight?
4. Benefits of Radiation Therapy Outweigh Risks of a Second Cancer: Study
5. New Therapy for Enlarged Prostate May Bypass Unpleasant Side Effects
6. For potentially crippling dystonia, earlier deep brain therapy gets better, quicker results
7. Scientists devise targeted therapy strategy for rare form of childhood cancer
8. FDA approves ipilimumab, an immunotherapy, to treat metastatic melanoma
9. Novel immunotherapy drug receives FDA approval for the treatment of metastatic melanoma
10. Interest in Toys May Predict Success of Autism Home Therapy
11. Short Course of Hormone Therapy Boosts Prostate Cancer Survival: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... ... 27, 2017 , ... Drs. Bruce Trimble and Michelle Parker ... a referral. Trimble Dental offers a variety of services to meet each patient’s ... patients have discolored, crooked or missing teeth in Eau Claire, WI, Drs. Trimble ...
(Date:3/27/2017)... Austin, TX (PRWEB) , ... March 27, 2017 , ... ... , Edward Buckingham MD, and his colleague, Sudeep Roy, MD, was recently published ... on Bipolar Electrocautery Efficacy in Rhytidectomy” details Drs. Buckingham and Roy’s study on the ...
(Date:3/27/2017)... ... 27, 2017 , ... The Case Management Society of America (CMSA) will install ... CMSA’s membership has elected their upcoming President-Elect, Secretary, Treasurer and two Directors to ... new VA Advisory position has also been added to the BOD, per an appointment ...
(Date:3/27/2017)... ... March 27, 2017 , ... EpiGentek ... to pursue the recent RNA methylation “gold rush” with their established portfolio of ... newfound characteristics of N6-methyladenosine, or m6A , RNA methylation has received a ...
(Date:3/27/2017)... ... March 27, 2017 , ... The Anaheim Hills office ... First National Capital has added 10 new sales professionals over the past 6 months ... by 15 additional new hires over the course of 2017. , “This new ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 2017 On Friday, benchmark US ... closed the trading session up 0.19%; the Dow Jones ... was down 0.08%. US markets made broad based gains ... in green. Pre-market today, Stock-Callers.com reviews these four Medical ... WMGI), Amedica Corporation (NASDAQ: AMDA), MiMedx Group Inc. (NASDAQ: ...
(Date:3/27/2017)... , March 27, 2017  Impax Laboratories, Inc. (NASDAQ: ... Paul M. Bisaro as Impax,s President and ... Board, effective March 27, 2017. Mr. Bisaro will succeed ... Interim President and Chief Executive Officer since December of ... and branded pharmaceutical experience, Mr. Bisaro, 56, is an ...
(Date:3/27/2017)... , March 27, 2017 Arena Pharmaceuticals, Inc. ... on developing novel, small molecule drugs across multiple therapeutic areas, ... Chief Executive Officer, will present a corporate update at the ... 3:40pm ET.  The conference will take place April 4-5, 2017 ... New York , NY.  A live ...
Breaking Medicine Technology: